Athersys Inc. and Healios complete deal to expand their MultiStem partnership

Cleveland biotechnology company Athersys Inc. (NASDAQ:ATHX) has reached an agreement with Japanese drugmaker Healios KK to broaden their collaboration into new therapeutic areas.

Under terms of the deal, Healios obtained exclusive licenses for the development and commercialization in Japan of Athersys’ MultiStem therapy for the treatment of acute respiratory distress syndrome (ARDS).

Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell. Originally published June 7, 2018.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: